Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment
volcanocorp.com

See what CB Insights has to offer

Founded Year

2000

Stage

Acq - P2P | Acquired

Total Raised

$17.67M

Valuation

$0000 

Revenue

$0000 

About Volcano Corporation

Volcano Corporation provides intravascular imaging for coronary and peripheral applications, and physiology. The company also offers a suite of peripheral therapeutic devices. The company's broad range of technologies makes imaging and therapy simpler, more informative and less invasive and offers physicians and their patients around the world with tools that aid diagnosis and guide and provide therapy. Founded in cardiovascular care and expanding into other specialties, Volcano is focused on improving patient and economic outcomes.

Volcano Corporation Headquarter Location

3661 Valley Centre Drive Suite 200

San Diego, California, 92130,

United States

916-638-8008

Latest Volcano Corporation News

Global Inferior Vena Cava Market (2021 to 2026) - Featuring ALN, Argon Medical and Cook Medical Among Others - ResearchAndMarkets.com

Sep 7, 2021

Volcano Corporation An inferior vena cava filter (IVC) is a medical device that is implanted into the inferior vena cava for deep venous thrombosis (DVT) or pulmonary embolism (PE). It is used in patients who are at high risk of developing a PE and cannot be sufficiently anticoagulated. They can either be permanent or retrievable; the latter though poses a challenge to the market as negligence in timely removal has been a concern. Factors driving the inferior vena cava filter are high increased research and development expenditures, growth in the cardiac devices market, rising healthcare spending in emerging economies, and technology spillover in nascent markets. Geographically, North America and Europe dominate the IVC filter market while the Asia Pacific is a region of high growth. Caval interruption to prevent pulmonary embolism (PE) is a concept that is more than 100 years old, and at that time, an invasive vein ligation surgery was warranted because it was believed to confer tremendous benefit to the critically ill. So, when the significantly less invasive inferior vena cava (IVC) filter was invented, it was accepted and adopted rather quickly. Furthermore, It seems that transient contraindications to anticoagulation have become an off-label indication to deploy retrievable IVC filters. These transient contraindications include trauma, peripartum state, bleeding peptic ulcers, surgical bleeding complications, and recent biopsies or pending surgeries. The bottom line is simple: as retrievable IVC filter designs improve so that they become easier to deploy and remove, and their perceived increased risk of fracture, embolization and IVC wall penetration declines, their benefits will continue to outweigh their risks, and we will see continued growth in their use. The prevalence of VTE is on a rise, across the globe. For instance, according to the Centers for Disease Control and Prevention (CDC), even though the precise number of people affected by VTE is unknown, however as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the United States. The Inferior Vena Cava Filter market is anticipated to grow at a high rate owing to this increasing prevalence. The advent of COVID-19 harmed the market of inferior vena cava during the year 2020. According to a report by the National Library of Medicine, venous registry volumes were reduced fivefold in the first quarter of 2020 compared with a similar period in 2019. The consequences of delaying vascular procedures for ambulatory venous practice remain unknown with increased morbidity likely. Challenges to determine venous thromboembolism mortality impact exist given difficulty in verifying "in-home and extended care facility" deaths. Further ramifications of a pandemic shutdown will likely be amplified if the postponement of elective vascular care extends beyond a short window of time. Moreover, a study put forward by Vascular and Interventional Radiology depicts that the number of PE response team (PERT) calls declined significantly during the period. There was an influx of physicians caring for COVID-19 patients who were not used to managing intensive care unit (ICU)-level patients, as there was an immense shortage of the required personnel. The rise in the demand for retrievable vena cava filters is expected to fuel the market during the forecast period. Retrievable vena cava filters are finding an expanding prophylactic application in new patient populations who may be at temporary risk for venous thromboembolism. Those at risk may include bariatric, orthopedic, trauma, neurosurgical, and cancer patients. They are also being increasingly used by physicians who are afraid of lawsuits. Furthermore, retrievable IVC filter designs improve so that they become easier to deploy and remove, and their perceived increased risk of fracture, embolization, and IVC wall penetration declines, their benefits will continue to outweigh their risks, and we will see continued growth in their use. Key Topics Covered:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Volcano Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Volcano Corporation is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Volcano Corporation Patents

Volcano Corporation has filed 517 patents.

The 3 most popular patent topics include:

  • Medical imaging
  • Vascular diseases
  • Vascular procedures
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/29/2015

1/18/2022

Medical ultrasonography, Ultrasound, Drumhead lutes, Medical imaging, Medical equipment

Grant

Application Date

7/29/2015

Grant Date

1/18/2022

Title

Related Topics

Medical ultrasonography, Ultrasound, Drumhead lutes, Medical imaging, Medical equipment

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.